OPEN ACCESS Freely available online

Journal of Developing Drugs

ISSN: 2329-6631

Perspective

Nanomedicine and the Evolution of Targeted Drug Delivery

Alexander Scott*

Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

DESCRIPTION

Nanomedicine refers to the application of nanotechnology in disease diagnosis, prevention and treatment through the use of materials typically ranging from 1 to 100 nanometres. At this scale, materials possess unique physicochemical characteristics that differ substantially from their bulk counterparts. These properties enable nanoparticles to interact more effectively with biological systems, providing opportunities for controlled drug release, improved bioavailability and selective targeting of diseased tissues. One of the most significant contributions of nanomedicine is its role in targeted drug delivery. Conventional medications are often distributed throughout the body after administration, exposing healthy tissues to unnecessary drug concentrations and increasing the risk of adverse effects. Nanocarriers, including liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles and lipid nanoparticles, can encapsulate therapeutic agents and preferentially accumulate at disease sites. This targeted approach not only enhances therapeutic efficacy but also reduces systemic toxicity, particularly in diseases requiring long term treatment. Cancer therapy has demonstrated the remarkable clinical potential of nanomedicine. Traditional chemotherapy remains associated with severe adverse effects because cytotoxic drugs damage both malignant and healthy cells. Nanotechnology based delivery systems have improved the localisation of anticancer agents within tumour tissues through passive and active targeting mechanisms. Several nanoformulations have already become part of routine clinical practice, illustrating how nanotechnology can successfully bridge laboratory discoveries and patient care. Future developments incorporating tumour specific ligands and multifunctional nanoparticles may further enhance treatment precision while overcoming drug resistance.

Beyond oncology, nanomedicine is making substantial contributions to the management of infectious diseases, cardiovascular disorders, neurological conditions, inflammatory diseases and metabolic disorders. The rapid development of lipid nanoparticle based messenger RNA (Ribonuclic Acid) vaccines demonstrated the extraordinary potential of nanotechnology during global public health emergencies. This achievement highlighted that nanomedicine is no longer an experimental concept but an established platform capable of supporting rapid therapeutic innovation. Similar technologies are now being investigated for vaccines against various infectious diseases and for personalised immunotherapies. Neurological disorders represent another area where nanomedicine offers considerable promise. The blood-brain barrier remains a major obstacle for many therapeutic agents. Engineered nanoparticles designed to cross or bypass this barrier may enable more effective treatment of Alzheimer's disease, Parkinson's disease, brain tumours and other central nervous system disorders. Although many of these approaches remain under clinical investigation, their potential to improve neurological drug delivery is highly encouraging.

Recent advances in nanomedicine increasingly rely on interdisciplinary collaboration. Artificial intelligence and machine learning are beginning to accelerate nanoparticle design by predicting optimal formulations, evaluating stability and identifying promising drug carrier combinations. Computational modelling can substantially reduce experimental workload and improve the efficiency of formulation development. Meanwhile, personalised medicine is creating opportunities to tailor nanoparticle based therapies according to individual patient characteristics, genetic profiles and disease biomarkers. Such integration may ultimately produce highly individualised therapeutic strategies with improved clinical outcomes. Small variations in particle size, surface charge, or composition may significantly influence therapeutic performance and safety. Regulatory agencies continue to refine evaluation frameworks for nanomedicines because conventional pharmaceutical assessment methods may not fully capture the unique properties of nanoscale materials. Harmonised international standards will therefore be essential for facilitating global development and approval.

Long term safety also requires careful consideration. While many nanomaterials exhibit favourable biocompatibility, incomplete understanding of their long term biodistribution, metabolism and environmental impact continues to raise important scientific questions. Comprehensive toxicological investigations should accompany technological innovation to ensure patient safety. Another important consideration is accessibility.

Correspondence to: Alexander Scott, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland, E-mail: alexander.scott@gmail.com

Received: 05-Jan-2026, Manuscript No. EOED-26-43967; **Editor assigned:** 07-Jan-2026, PreQC No. EOED-26-43967 (PQ); **Reviewed:** 21-Jan-2026, QC No. EOED-26-43967; **Revised:** 28-Jan-2026, Manuscript No. EOED-26-43967 (R); **Published:** 04-Feb-2026, DOI: 10.35841/2329-6631.26.15.261

Citation: Scott A (2026). Nanomedicine and the Evolution of Targeted Drug Delivery. J Develop Drugs. 15:261.

Copyright: © Scott A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Advanced nanomedicine products often require sophisticated manufacturing technologies that increase production costs. Without strategies to improve affordability, the benefits of nanomedicine may remain concentrated in high-income healthcare systems. Collaborative efforts involving academic institutions, pharmaceutical companies, regulatory agencies and policymakers will be necessary to develop cost effective manufacturing processes and equitable distribution models.